September 20, 2011 – FerroKin BioSciences announced on September 19 that the first dose has been administered in an international Phase 2 study of FBS0701, a novel once-daily oral iron chelator in development for the treatment of transfusional iron overload. This is an Open Label, Multi-Center, Single-Dose Pharmacokinetics, and Multiple Dose Study of the Safety, […]
September 10, 2010 – FerroKin BioSciences has announced the initiation of an international Phase 2 study of FBS0701, a novel once-daily iron chelator in development for the treatment of transfusional iron overload. The Phase 2 study will assess the safety, tolerability, and pharmacodynamics of FBS0701. “We are excited about the potential of FBS0701 in treating […]
November 30, 2009 – FerroKin BioSciences, Inc. has announced a Phase 1B trial to study the safety and pharmacology of its new oral iron chelator, FBS0701. A total of 16 patients will be enrolled in the study at centers in the U.S., Australia and Italy. Eligibility In general, patients can qualify for […]
